2024年印度制药行业报告

Executive Summary3Advantage India4Market Overview6Recent Trends and Strategies13Growth Drivers18Opportunities27Key Industry Contacts29Appendix31 Executive summary 5. Robust growth in biotechindustry 1.Leading pharma producer •AccordingtoarecentEYFICCIreport,astherehasbeenagrowingconsensusoverprovidingnew innovative therapies topatients,Indianpharmaceuticalmarketisestimatedto touch US$130 billion invaluebytheendof2030andUS$450billionmarketby2047. •Indiaisamongthetop12destinationsforbiotechnologyworldwideandthirdlargestinAsiaPacific.Thecountryholds3-5%oftheglobal biotechnology industry pie.In2022,India’s bioeconomywas valued atUS$137billion,andaimstoachieveUS$300billionmarkby2030. •Indiaranks3rdworldwideforpharmaceuticalproductionbyvolumeand14th by value.The country has anestablisheddomesticpharmaceuticalindustry,withastrongnetworkof3,000drugcompaniesand~10,500manufacturingunits. 4. Rapidly growinghealthcare sector •TheIndianhealthcareindustryreached overUS$370 billion in 2022 and isexpectedtoreachoverUS$610billionby2026.•Indianhospitalmarket valuedatUS$98.98billioninFY23andprojectedtogrowby 8%CAGR and reached toUS$193.59billionbyFY32. 2. One of the highestexports •India’sdrugsandpharmaceuticalsexportsstoodatUS$27.82billioninFY24(April-March)andstandsatUS$14.42billioninFY25(April-September).•According to Government data,theIndianpharmaceuticalindustryis worth approximatelyUS$50billionwithoverUS$25billionof the value coming fromexports.•About20%oftheglobalexportsingenericdrugsaremetbyIndia. 3. Among fastest growing industries•DuringFY18toFY23,theIndianpharmaceuticalindustryloggedacompoundannualgrowthrate(CAGR)of6- 8%,primarilydrivenbyan8%increaseinexportsanda6%riseinthedomesticmarket. •TheIndianpharmaceuticalindustryhasseenamassiveexpansionoverthelastfewyearsandisexpectedtoreachabout 13%of the size of the global pharma market while enhancing its quality,affordability,andinnovation.•IndianpharmaceuticalsectorisexpectedtogrowataCAGRof22.4%inthenearfuture.ThegovernmenthassetambitioustargettoboostthemedicaldevicesindustryinIndia,aimingtoelevateitfromitscurrentUS$11billionvaluation to US$50 billion by 2030.India is the second-largest contributor of global biotech andpharmaceuticalworkforce.•Exportsofdrugsandpharmaceuticalsrecordedastrongy-o-ygrowthof9.7%duringApril-MarchFY24. Advantage India 3. POLICY SUPPORT 2. ECONOMIC DRIVERS •ThePLIschemeforpharmaceuticalsisbeingimplementedwithatotaloutlayoftheUS$2.04billion(Rs.15,000 crore)spanning from 2020-21 to 2028-29,to boost India'smanufacturingcapacity,elevateinvestment,anddiversifyproductofferingsinthesector.•TheUnionCabinet,onApril26,2023,approvedtheNationalMedicalDevicesPolicy, 2023.The National Medical Devices Policy,2023 is expected to facilitate an orderlygrowthof the medical device sector to meet the public health objectives of access,affordability,qualityandinnovation.•StrengtheningofPharmaceuticalIndustry(SPI):TheMinistry'sscheme“StrengtheningofPharmaceuticalIndustry(SPI)withatotalfinancialoutlayofRs.500crore(US$60.6million)extends support required to existing pharma clusters and MSMEs across thecountrytoimprovetheirproductivity,qualityandsustainability.•PradhanMantriBhartiyaJanAushadhiKendras(PMBJKs):TheGovernmenthassetatargettoincreasethenumberofPMBJKsto10,500bytheendofMarch2025.ProductbasketofPMBJPcomprisesof1,451drugsand240surgicalinstruments. ▪The total market size of the Indian Pharma Industry isexpectedtoreachUS$130billionby2030andUS$450billionmarketby2047.▪ThedomesticpharmaceuticalindustrywouldlikelyreachUS$57billionbyFY25andseeanincreaseinoperatingmarginsof100-150basispoints(bps).▪Indianpharmaceuticalcompaniesareprojectedtoachievearevenue growth of 9-11%in FY25.This growth isexpectedto be fueled by robust performances in keymarkets,including the United States,Europe,andemergingregions.▪India has the largest number of USFDA-compliantpharmaceuticalplants outside the US and over 2,000WHO-GMPapprovedfacilities,servingdemandfrom150+countriesworldwide,with10,500+manufacturingfacilities. 4. INCREASINGINVESTMENTS ▪Up to 100%,FDI has been allowedthroughautomatic route for Greenfieldpharmaceuticalsprojects.For Brownfieldpharmaceuticalsprojects,FDI allowed isupto 74%through automatic route andbeyondthatthroughgovernmentapproval.▪The cumulative FDI equity inflow in theDrugsand Pharmaceuticals industry isUS$22.52 billionduring the period April2000-March2024,almost3.4%ofthetotalinflowreceivedacrosssectors.▪In the Interim Budget 2024-25,thegovernmentearmarked US$120 million(Rs1,000crore)forthepromotionofbulkdrugparksforFY25,asignificantincreasefromthepreviousyear. 1. COST EFFICIENCY ▪Indiahasemrgedasthemedialtourismhuboftheworldprovidingcost-effectivetreatmentswiththelatesttechnologyenabledby several pathbreaking reformsandprovisionsinhealthcaresector. ▪Access to affordable HIV treatment fromIndiaisoneofthegreatestsuccessstoriesinmedicine.India is one of the biggestsuppliersoflow-costvaccinesintheworld,therebyrightlymakingitthe‘PharmacyoftheW